Skip to main content
Cutia Therapeutics logo

Cutia Therapeutics — Investor Relations & Filings

Ticker · 2487 HKEX Manufacturing
Open in API
Filings indexed 176 across all filing types
Latest filing 2026-04-27 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2487

About Cutia Therapeutics

http://www.cutiatx.com

Cutia Therapeutics is an R&D-driven biopharmaceutical platform established in 2019, specializing in the research, development, manufacture, and commercialization of dermatological treatments. The company is dedicated to providing a comprehensive suite of innovative, safe, and effective solutions for patients and consumers. Its core therapeutic focus areas include the management of localized adipose accumulation and various scalp diseases. As a dermatology-focused entity, Cutia maintains a dedicated pipeline emphasizing novel candidates, including those targeting the Immune System domain.

Recent filings

Filing Released Lang Actions
CHANGE OF NAME OF PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE AND REGISTERED OFFICE IN THE CAYMAN ISLANDS
Regulatory Filings Classification · 1% confidence The document is a brief corporate announcement filed on the Hong Kong Stock Exchange regarding the change of name of the company’s principal share registrar and registered office in the Cayman Islands. It does not report financial results, dividends, board appointments, or any specific report publication; it is a general regulatory announcement. Therefore it falls under the fallback category “Regulatory Filings” (RNS).
2026-04-27 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 26 JUNE 2026
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a Form of Proxy for the Annual General Meeting (AGM) of Cutia Therapeutics, soliciting shareholder votes on resolutions. It is not the AGM presentation nor the results notice, but rather proxy solicitation materials sent to shareholders to request voting instructions ahead of the meeting. This matches the definition for Proxy Solicitation & Information Statement (PSI).
2026-04-24 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 1% confidence The document is the formal notice convening the Company’s Annual General Meeting, listing date, venue and the ordinary resolutions to be proposed at the AGM. It is not the full Annual Report or earnings release but specifically an AGM notice. Therefore, the correct classification is AGM Information.
2026-04-24 English
(1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES (3) PROPOSED RE-APPOINTMENT OF AUDITOR AND (4) NOTICE OF ANNUAL GENERA
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a shareholder circular containing notice of the Annual General Meeting, proposed resolutions (re-election of directors, share repurchase/issuance mandates, auditor re-appointment), explanatory statements, and a proxy form. It is not the full annual report or financial statements, nor just an announcement of publication; it is clearly soliciting shareholder votes. This matches the definition of Proxy Solicitation & Information Statement (PSI).
2026-04-24 English
2025 Environmental, Social and Governance Report
Regulatory Filings
2026-04-24 English
2025 Annual Report
Annual Report Classification · 1% confidence The document is explicitly titled 'Annual Report 2025' for Cutia Therapeutics. It contains comprehensive sections including the Chairman's Statement, Management Discussion and Analysis, Financial Highlights, Corporate Governance, and full consolidated financial statements (Profit or Loss, Financial Position, Cash Flows, etc.). It meets all the criteria for a formal annual report. FY 2025
2026-04-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.